Autopsy report · NCT02228382
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 5 years 11 months before it stopped.
- 163 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Previously Treated PH + CML
- Interventions
- Bosutinib
- Participants
- 163
- Sites
- 48
- Countries
- Austria, France, Germany, Italy, Norway, Spain, Sweden, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.